Lonza says its presence in China is growing despite a short-term talent shortage in the industry. “The Chinese pharma market is big and growing very quickly [with] a lot of molecules that are in development,†Lonza’s general manager of China, Hong Pan, tells BioProcess Insider. “China was very generically driven but more companies are putting their money into innovative pharma. The added growth is due to a few factors, [such as] the increased wealth of the population. People are getting…
The US FDA has approved a fourth product for Seagen and the twelfth ADC therapeutic in the form of cervical cancer drug Tivdak. First up, it’s Seagen (previously Seattle Genetics), which received accelerated approval for Tivdak (tisotumab vedotin), an antibody drug conjugate (ADC) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. On a conference call discussing the approval, Seagen CEO Clay Siegall described the approval as “another significant milestone 
Oxford Biomedica will add 39,000 square feet of advanced manufacturing space at its Oxbox site in the UK following an investment from the Serum Institute of India. The £50 million ($68 million) investment from Indian vaccine giant Serum Institute of India will be used to develop the fallow area at Oxford Biomedica’s ‘Oxbox’ viral vector manufacturing site in Oxford, UK. In return, Serum Institute of India – through its subsidiary Serum Life Sciences – will acquire a 3.9% stake in…